Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Colorcon
AstraZeneca
McKinsey
Medtronic

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

OVIDREL Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Ovidrel patents expire, and what generic alternatives are available?

Ovidrel is a drug marketed by Emd Serono and is included in one NDA. There is one patent protecting this drug.

This drug has eighteen patent family members in fourteen countries.

The generic ingredient in OVIDREL is choriogonadotropin alfa. One supplier is listed for this compound. Additional details are available on the choriogonadotropin alfa profile page.

Summary for OVIDREL
International Patents:18
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 26
Drug Prices: Drug price information for OVIDREL
DailyMed Link:OVIDREL at DailyMed
Drug patent expirations by year for OVIDREL
Drug Prices for OVIDREL

See drug prices for OVIDREL

Generic Entry Opportunity Date for OVIDREL
Generic Entry Date for OVIDREL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OVIDREL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of VirginiaN/A
Meir Medical CenterN/A
Reproductive & Genetic Hospital of CITIC-XiangyaN/A

See all OVIDREL clinical trials

Pharmacology for OVIDREL
Drug ClassGonadotropin

US Patents and Regulatory Information for OVIDREL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OVIDREL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000   Start Trial   Start Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Moodys
Harvard Business School
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.